HIV-1-IN-85
HIV-1-IN-85 is an orally active HIV-1 inhibitor (IC50 = 72 nM). HIV-1-IN-85 exhibits strong inhibitory activity against wild-type (WT) HIV-1 and NNRTI-resistant single mutant strains (L100I, K103N, Y181C, Y188L, E138K) and moderate efficacy against double mutant strains (F227L+V106A, RES056). HIV-1-IN-85 shows good in vivo safety in ICR mice. HIV-1-IN-85 can be used for the study of HIV-1 infection.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- 화학식: C27H20FN5
- 분자량:433.48
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
IC50 & Target
[1]|
HIV-1 72 nM (IC50) |
HIV-1 (WT) 3.7 nM (EC50) |
HIV-1 (L100I) 9.2 nM (EC50) |
HIV-1 (K103N) 5.8 nM (EC50) |
HIV-1 (Y181C) 3.7 nM (EC50) |
HIV-1 (Y188L) 231 nM (EC50) |
HIV-1 (E138K) 30 nM (EC50) |
HIV-1 (F227L+V106A) 2399 nM (EC1.5) |
HIV-1 (RES056) 277 nM (EC50) |
In Vitro
HIV-1-IN-85 (Compound (S)-5m) exhibits potent antiviral activity against WT HIV-1 and single mutant strains in MT-4 cells, with EC50 values of 3.7 nM (WT), 9.2 nM (L100I), 5.8 nM (K103N), 37 nM (Y181C), 231 nM (Y188L), 30 nM (E138K), 2399 nM (F227L+V106A) and 277 nM (RES056)[1].
HIV-1-IN-85 inhibits the polymerase activity of WT HIV-1 (IC50 = 72 nM) in enzyme-level assays[1].
HIV-1-IN-85 (40 μM, 24 h) has minimal effect on mitochondrial function in MT-4 cells and exhibits negligible inhibition on the hERG channel[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR mice[1]
-
Dosage:2 g/kg
-
Administration:p.o., single dose, 2 weeks observation
-
Result:Showed good in vivo safety in ICR mice, with no deaths or abnormal behaviors, no significant differences in body weight.
Showed no obvious pathological damage in brain, heart, liver, spleen, lung and kidney.
Chemical Information
-
분자량 433.48
-
화학식 C27H20FN5
-
SMILES
CC1=CC(C2=CC=C(C=C2)C#N)=CC(C)=C1[C@@H](C3=CC=NC(NC4=CC=C(C=C4)C#N)=N3)F
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocol
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)